Andrew Berchuck

Overview:

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Positions:

James M. Ingram Professor of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Chief of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1980

Case Western Reserve University

Grants:

Tissue and Data Acquisition Activity for the Study of Gynecologic Disease

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date

Mutation analysis of pap smear samples and associated tissues for ovarian cancer diagnostics

Administered By
Pathology
Role
Principal Investigator
Start Date
End Date

Tissue and Data Acquisition Activity for the Study of Gynecologic Disease

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date

Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date

Janet Burros Ovarian Cancer Repository

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Co Investigator
Start Date
End Date

Publications:

Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.

BACKGROUND: Randomized trials have reported conflicting findings on survival for advanced-stage ovarian cancer treated with primary debulking surgery (PDS) versus neoadjuvant chemotherapy with interval debulking; surgical complications and mortality are higher with PDS. We assessed women's preferences for tradeoffs related to this important clinical decision. METHODS: Ovarian cancer patients were recruited to complete a discrete-choice experiment (DCE) consisting of 8 choice tasks presenting experimentally designed treatment alternatives in terms of treatment order, extent of surgery including risk of ostomy, chance of death from surgical complications (1%-10%), readmission for surgical complications (5%-50%), progression-free survival (1-3 years), and overall survival (3-5 years). Random-parameters logit regression was applied to model participants' choices as a function of attribute levels. RESULTS: A total of 101 ovarian cancer survivors completed the DCE survey; of these participants, 30% were receiving chemotherapy at the time, and 33% had prior recurrence. Overall survival was of greatest importance to participants (36/100), followed by risk of readmission due to complications (23/100), progression-free survival (19/100), surgical mortality (16/100), extent of surgery (4/100), and order of surgery and chemotherapy (2/100). Overall, the participants would tolerate a 15-percentage point increase in risk of major complications (95% confidence interval [CI], 3%-29%) or a 4-percentage point increase in the risk of surgical mortality (95% CI, 2%-13%) in order to increase their expected overall survival from 3 to 3.5 years. CONCLUSIONS: Patients would accept a moderately higher risk of perioperative complications and surgical mortality in exchange for substantial gains in survival. These quantitative findings provide clinicians with a framework to discuss preferences with patients and to incorporate preferences into clinical trial design.
Authors
Havrilesky, LJ; Yang, J-C; Lee, PS; Secord, AA; Ehrisman, JA; Davidson, B; Berchuck, A; Darcy, KM; Maxwell, GL; Reed, SD
MLA Citation
URI
https://scholars.duke.edu/individual/pub1406386
PMID
31454432
Source
pubmed
Published In
Cancer
Published Date
DOI
10.1002/cncr.32447

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.
Authors
Rambau, PF; Vierkant, RA; Intermaggio, MP; Kelemen, LE; Goodman, MT; Herpel, E; Pharoah, PD; Kommoss, S; Jimenez-Linan, M; Karlan, BY; Gentry-Maharaj, A; Menon, U; Polo, SH; Candido Dos Reis, FJ; Doherty, JA; Gayther, SA; Sharma, R; Larson, MC; Harnett, PR; Hatfield, E; de Andrade, JM; Nelson, GS; Steed, H; Schildkraut, JM; Carney, ME; Høgdall, E; Whittemore, AS; Widschwendter, M; Kennedy, CJ; Wang, F; Wang, Q; Wang, C; Armasu, SM; Daley, F; Coulson, P; Jones, ME; Anglesio, MS; Chow, C; de Fazio, A; García-Closas, M; Brucker, SY; Cybulski, C; Harris, HR; Hartkopf, AD; Huzarski, T; Jensen, A; Lubiński, J; Oszurek, O; Benitez, J; Mina, F; Staebler, A; Taran, FA; Pasternak, J; Talhouk, A; Rossing, MA; Hendley, J; AOCS Group,; Edwards, RP; Fereday, S; Modugno, F; Ness, RB; Sieh, W; El-Bahrawy, MA; Winham, SJ; Lester, J; Kjaer, SK; Gronwald, J; Sinn, P; Fasching, PA; Chang-Claude, J; Moysich, KB; Bowtell, DD; Hernandez, BY; Luk, H; Behrens, S; Shah, M; Jung, A; Ghatage, P; Alsop, J; Alsop, K; García-Donas, J; Thompson, PJ; Swerdlow, AJ; Karpinskyj, C; Cazorla-Jiménez, A; García, MJ; Deen, S; Wilkens, LR; Palacios, J; Berchuck, A; Koziak, JM; Brenton, JD; Cook, LS; Goode, EL; Huntsman, DG; Ramus, SJ; Köbel, M
MLA Citation
Rambau, Peter F., et al. “Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study..” The Journal of Pathology. Clinical Research, vol. 4, no. 4, Oct. 2018, pp. 250–61. Epmc, doi:10.1002/cjp2.109.
URI
https://scholars.duke.edu/individual/pub1338219
PMID
30062862
Source
epmc
Published In
The Journal of Pathology. Clinical Research
Volume
4
Published Date
Start Page
250
End Page
261
DOI
10.1002/cjp2.109

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC. Comprehensive genomic and phenotypic analysis of the RCC subtypes reveals distinctive features of each subtype that provide the foundation for the development of subtype-specific therapeutic and management strategies for patients affected with these cancers. Somatic alteration of BAP1, PBRM1, and PTEN and altered metabolic pathways correlated with subtype-specific decreased survival, while CDKN2A alteration, increased DNA hypermethylation, and increases in the immune-related Th2 gene expression signature correlated with decreased survival within all major histologic subtypes. CIMP-RCC demonstrated an increased immune signature, and a uniform and distinct metabolic expression pattern identified a subset of metabolically divergent (MD) ChRCC that associated with extremely poor survival.
Authors
Ricketts, CJ; De Cubas, AA; Fan, H; Smith, CC; Lang, M; Reznik, E; Bowlby, R; Gibb, EA; Akbani, R; Beroukhim, R; Bottaro, DP; Choueiri, TK; Gibbs, RA; Godwin, AK; Haake, S; Hakimi, AA; Henske, EP; Hsieh, JJ; Ho, TH; Kanchi, RS; Krishnan, B; Kwiatkowski, DJ; Lui, W; Merino, MJ; Mills, GB; Myers, J; Nickerson, ML; Reuter, VE; Schmidt, LS; Shelley, CS; Shen, H; Shuch, B; Signoretti, S; Srinivasan, R; Tamboli, P; Thomas, G; Vincent, BG; Vocke, CD; Wheeler, DA; Yang, L; Kim, WY; Robertson, AG; Cancer Genome Atlas Research Network,; Spellman, PT; Rathmell, WK; Linehan, WM
MLA Citation
Ricketts, Christopher J., et al. “The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma..” Cell Rep, vol. 23, no. 1, Apr. 2018, pp. 313-326.e5. Pubmed, doi:10.1016/j.celrep.2018.03.075.
URI
https://scholars.duke.edu/individual/pub1311444
PMID
29617669
Source
pubmed
Published In
Cell Reports
Volume
23
Published Date
Start Page
313
End Page
326.e5
DOI
10.1016/j.celrep.2018.03.075

Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Background: Polycystic ovary syndrome (PCOS), and one of its distinguishing characteristics, oligomenorrhea, have both been associated with ovarian cancer risk in some but not all studies. However, these associations have been rarely examined by ovarian cancer histotypes, which may explain the lack of clear associations reported in previous studies.Methods: We analyzed data from 14 case-control studies including 16,594 women with invasive ovarian cancer (n = 13,719) or borderline ovarian disease (n = 2,875) and 17,718 controls. Adjusted study-specific ORs were calculated using logistic regression and combined using random-effects meta-analysis. Pooled histotype-specific ORs were calculated using polytomous logistic regression.Results: Women reporting menstrual cycle length >35 days had decreased risk of invasive ovarian cancer compared with women reporting cycle length ≤35 days [OR = 0.70; 95% confidence interval (CI) = 0.58-0.84]. Decreased risk of invasive ovarian cancer was also observed among women who reported irregular menstrual cycles compared with women with regular cycles (OR = 0.83; 95% CI = 0.76-0.89). No significant association was observed between self-reported PCOS and invasive ovarian cancer risk (OR = 0.87; 95% CI = 0.65-1.15). There was a decreased risk of all individual invasive histotypes for women with menstrual cycle length >35 days, but no association with serous borderline tumors (Pheterogeneity = 0.006). Similarly, we observed decreased risks of most invasive histotypes among women with irregular cycles, but an increased risk of borderline serous and mucinous tumors (Pheterogeneity < 0.0001).Conclusions: Our results suggest that menstrual cycle characteristics influence ovarian cancer risk differentially based on histotype.Impact: These results highlight the importance of examining ovarian cancer risk factors associations by histologic subtype. Cancer Epidemiol Biomarkers Prev; 27(2); 174-82. ©2017 AACR.
Authors
Harris, HR; Babic, A; Webb, PM; Nagle, CM; Jordan, SJ; Risch, HA; Rossing, MA; Doherty, JA; Goodman, MT; Modugno, F; Ness, RB; Moysich, KB; Kjær, SK; Høgdall, E; Jensen, A; Schildkraut, JM; Berchuck, A; Cramer, DW; Bandera, EV; Wentzensen, N; Kotsopoulos, J; Narod, SA; Phelan, CM; McLaughlin, JR; Anton-Culver, H; Ziogas, A; Pearce, CL; Wu, AH; Terry, KL; Ovarian Cancer Association Consortium,; Australian Ovarian Cancer Study Group,
MLA Citation
Harris, Holly R., et al. “Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium..” Cancer Epidemiol Biomarkers Prev, vol. 27, no. 2, Feb. 2018, pp. 174–82. Pubmed, doi:10.1158/1055-9965.EPI-17-0655.
URI
https://scholars.duke.edu/individual/pub1286353
PMID
29141849
Source
pubmed
Published In
Cancer Epidemiol Biomarkers Prev
Volume
27
Published Date
Start Page
174
End Page
182
DOI
10.1158/1055-9965.EPI-17-0655

Is There a Role for Ovarian Cancer Screening in High-Risk Women?

Authors
Berchuck, A; Havrilesky, LJ; Kauff, ND
MLA Citation
Berchuck, Andrew, et al. “Is There a Role for Ovarian Cancer Screening in High-Risk Women?.” J Clin Oncol, vol. 35, no. 13, May 2017, pp. 1384–86. Pubmed, doi:10.1200/JCO.2016.72.0045.
URI
https://scholars.duke.edu/individual/pub1250438
PMID
28447911
Source
pubmed
Published In
Journal of Clinical Oncology
Volume
35
Published Date
Start Page
1384
End Page
1386
DOI
10.1200/JCO.2016.72.0045

Research Areas:

3' Untranslated Regions
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
5-Lipoxygenase-Activating Proteins
ABO Blood-Group System
ATP-Binding Cassette, Sub-Family B, Member 1
Acetaminophen
Actins
Actomyosin
Actuarial Analysis
Adaptor Proteins, Signal Transducing
Adenocarcinoma
Adenocarcinoma, Clear Cell
Adenocarcinoma, Mucinous
Adnexa Uteri
Adnexal Diseases
Adolescent
Adult
African Americans
African Continental Ancestry Group
Age Distribution
Age Factors
Age of Onset
Aged
Aged, 80 and over
Alcohol Dehydrogenase
Algorithms
Alkylating Agents
Alleles
Alternative Splicing
Americas
Amidohydrolases
Amino Acid Sequence
Aminopeptidases
Amnion
Analysis of Variance
Anemia
Aneuploidy
Angiogenic Proteins
Animals
Anthropometry
Anti-Inflammatory Agents, Non-Steroidal
Antibodies
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antidepressive Agents
Antigens, CD
Antigens, CD31
Antigens, CD45
Antigens, CD80
Antigens, Tumor-Associated, Carbohydrate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Apolipoprotein A-I
Apoptosis
Apoptosis Regulatory Proteins
Arylamine N-Acetyltransferase
Ascites
Ascitic Fluid
Autophagy
Azacitidine
B7-1 Antigen
BRCA1 Protein
BRCA2 Protein
Base Sequence
Bayes Theorem
Binding Sites
Biopsy
Biopsy, Needle
Blood Coagulation
Blood Coagulation Disorders
Blood Coagulation Tests
Blood Loss, Surgical
Blood Transfusion
Blotting, Northern
Blotting, Southern
Blotting, Western
Body Height
Body Mass Index
Bone Marrow Transplantation
Brachytherapy
Brain Neoplasms
Breast
Breast Neoplasms
CA-125 Antigen
Cadherins
Caloric Restriction
Cancer
Carbon-Nitrogen Ligases
Carboplatin
Carcinoembryonic Antigen
Carcinoma
Carcinoma in Situ
Carcinoma, Adenoid Cystic
Carcinoma, Endometrioid
Carcinoma, Papillary
Carcinoma, Signet Ring Cell
Carcinoma, Small Cell
Carcinoma, Squamous Cell
Carcinosarcoma
Carrier Proteins
Case-Control Studies
Caspase 3
Caspase 8
Catalytic Domain
Cell Adhesion
Cell Culture Techniques
Cell Cycle
Cell Cycle Proteins
Cell Division
Cell Growth Processes
Cell Line
Cell Line, Transformed
Cell Line, Tumor
Cell Lineage
Cell Movement
Cell Proliferation
Cell Shape
Cell Survival
Cell Transformation, Neoplastic
Cells, Cultured
Cervix Uteri
Cesarean Section
Chemotherapy
Chemotherapy, Adjuvant
Chi-Square Distribution
Chickens
Child
Child, Preschool
Chloramphenicol O-Acetyltransferase
Choriocarcinoma
Chorionic Gonadotropin
Chromatin
Chromatography, Affinity
Chromatography, Liquid
Chromium
Chromium Compounds
Chromosome Aberrations
Chromosome Deletion
Chromosome Mapping
Chromosomes, Human, Pair 1
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 17
Chromosomes, Human, Pair 18
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 2
Chromosomes, Human, Pair 3
Chromosomes, Human, Pair 4
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Chromosomes, Human, Pair 8
Chromosomes, Human, Pair 9
Cisplatin
Clinical Competence
Clinical Trials as Topic
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clone Cells
Cloning, Molecular
Cluster Analysis
Codon
Cohort Studies
Coitus
Colectomy
Collagen
Colon
Colon, Sigmoid
Colonic Neoplasms
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Combined Modality Therapy
Comparative Effectiveness Research
Comparative Genomic Hybridization
Compliance
Condylomata Acuminata
Confidence Intervals
Confounding Factors (Epidemiology)
Contraception
Contraceptives, Oral
Contraceptives, Oral, Combined
Contraceptives, Oral, Hormonal
Cooperative Behavior
Cost-Benefit Analysis
Counseling
CpG Islands
Culture Media
Cyclin E
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinases
Cyclins
Cyclophosphamide
Cystadenocarcinoma
Cystadenocarcinoma, Papillary
Cystadenocarcinoma, Serous
Cystadenoma, Mucinous
Cystadenoma, Serous
Cysts
Cytochrome P-450 CYP1A1
Cytochrome P-450 CYP3A
Cytokines
Cytostatic Agents
DNA
DNA (Cytosine-5-)-Methyltransferase
DNA (Cytosine-5-)-Methyltransferases
DNA Copy Number Variations
DNA Damage
DNA Fingerprinting
DNA Helicases
DNA Ligases
DNA Methylation
DNA Mismatch Repair
DNA Mutational Analysis
DNA Polymerase II
DNA Primers
DNA Repair
DNA, Complementary
DNA, Neoplasm
DNA, Satellite
DNA, Single-Stranded
DNA-Binding Proteins
Dactinomycin
Data Collection
Decision Support Techniques
Decision Trees
Deoxyribonucleases, Type II Site-Specific
Depression, Chemical
Dermatologic Surgical Procedures
Developed Countries
Diacylglycerol Kinase
Diagnosis, Differential
Diet
Dietary Supplements
Diffusion of Innovation
Dihydrouracil Dehydrogenase (NADP)
Dinoprostone
Diploidy
Discriminant Analysis
Disease Models, Animal
Disease Progression
Disease-Free Survival
Diseases
Dormancy
Dosage Compensation, Genetic
Dose-Response Relationship, Drug
Down-Regulation
Doxorubicin
Drug Administration Schedule
Drug Combinations
Drug Design
Drug Resistance
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Drug Synergism
E2F Transcription Factors
Early Detection of Cancer
Education, Medical, Graduate
Eflornithine
Eggs
Electrophoresis, Polyacrylamide Gel
Endometrial Hyperplasia
Endometrial Neoplasms
Endometriosis
Endometrium
Endosomal Sorting Complexes Required for Transport
Environmental Exposure
Enzyme Induction
Enzyme Inhibitors
Enzyme-Linked Immunosorbent Assay
Epidermal Growth Factor
Epigenesis, Genetic
Epigenomics
Epithelial Cells
Epithelium
Epitopes
Epoxide Hydrolases
Estradiol
Estrogen Antagonists
Estrogen Receptor alpha
Estrogen Receptor beta
Estrogen Replacement Therapy
Estrogens
Ethics, Medical
Ethnic Groups
Etoposide
Europe
European Continental Ancestry Group
Evaluation Studies as Topic
Exome
Exons
Extracellular Space
Factor IX
Fallopian Tube Neoplasms
Fallopian Tubes
Family planning
Fatigue
Fellowships and Scholarships
Female
Fetal Diseases
Fibrin Fibrinogen Degradation Products
Fibroblast Growth Factor 2
Fibroblast Growth Factors
Fibroblasts
Fibronectins
Fistula
Flow Cytometry
Fluorescent Antibody Technique
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Folate Receptor 1
Folate Receptors, GPI-Anchored
Folic Acid
Follow-Up Studies
Forecasting
Formaldehyde
Frozen Sections
G1 Phase
GPI-Linked Proteins
GTP Phosphohydrolases
GTP-Binding Proteins
Galectin 1
Galectin 3
Gastrointestinal Diseases
Gene Amplification
Gene Deletion
Gene Dosage
Gene Expression
Gene Expression Profiling
Gene Expression Regulation
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Gene Frequency
Gene Silencing
Gene Transfer Techniques
Gene-Environment Interaction
Genes, BRCA1
Genes, BRCA2
Genes, Neoplasm
Genes, Tumor Suppressor
Genes, cdc
Genes, fms
Genes, p16
Genes, p53
Genes, ras
Genetic Association Studies
Genetic Heterogeneity
Genetic Linkage
Genetic Loci
Genetic Markers
Genetic Predisposition to Disease
Genetic Testing
Genetic Therapy
Genetic Variation
Genetics
Genital Diseases, Female
Genital Neoplasms, Female
Genome, Human
Genome-Wide Association Study
Genomic Imprinting
Genomic Instability
Genomics
Genotype
Germ-Line Mutation
Glycoproteins
Gonadotropins
Granulocyte Colony-Stimulating Factor
Gravity Suits
Great Britain
Green Fluorescent Proteins
Growth Inhibitors
Growth Substances
Gynecologic Surgical Procedures
Gynecology
Half-Life
Haplotypes
HeLa Cells
Head and Neck Neoplasms
Health Care Costs
Health Planning Guidelines
Health Resources
Hemagglutinins
Hemorrhage
Heparin
Hepatocyte Nuclear Factor 1-beta
Heterocyclic Compounds with 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
Heterozygote
Histones
Homeodomain Proteins
Homozygote
Hormone Replacement Therapy
Hormones
Humans
Hybrid Cells
Hydatidiform Mole
Hydrolysis
Hyperthermia, Induced
Hysterectomy
Image Processing, Computer-Assisted
Immunity
Immunoassay
Immunoblotting
Immunoenzyme Techniques
Immunohistochemistry
Immunologic Factors
Immunoradiometric Assay
Immunosuppressive Agents
Immunotherapy
Immunotoxins
In Situ Hybridization
Incidence
Infant
Infant, Newborn
Infection
Inflammation
Infusions, Parenteral
Injections, Intramuscular
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Integrins
Intercellular Signaling Peptides and Proteins
Interferon-gamma
Interleukin-1
Interleukin-18
Interleukin-1alpha
Interleukin-6
International Agencies
International Cooperation
Internship and Residency
Interviews as Topic
Intracellular Signaling Peptides and Proteins
Intraoperative Complications
Introns
Kaplan-Meier Estimate
Keratins
Ki-67 Antigen
Kidney Diseases
Kinetics
Laminin
Laparoscopy
Laparotomy
Leiomyoma
Leiomyosarcoma
Length of Stay
Leucine Zippers
Leukocyte Common Antigens
Life Expectancy
Life Tables
Linear Models
Linkage Disequilibrium
Liver Diseases
Logistic Models
Longitudinal Studies
Loss of Heterozygosity
Lovastatin
Luciferases
Luminescent Proteins
Lung Diseases
Lung Neoplasms
Lymph Node Excision
Lymph Nodes
Lymphatic Diseases
Lymphatic Metastasis
Lymphedema
Lymphocyte Activation
Lymphocytes
Lymphocytes, Tumor-Infiltrating
Lysophospholipids
MAP Kinase Kinase 4
MAP Kinase Signaling System
Macaca fascicularis
Macrophage Colony-Stimulating Factor
Magnetics
Male
Mammary Neoplasms, Experimental
Marketing
Markov Chains
Matrix Metalloproteinase 1
Maximum Tolerated Dose
Medical History Taking
Medical Oncology
Medicine
Mefenamic Acid
Membrane Glycoproteins
Membrane Proteins
Membrane Transport Proteins
Menarche
Menopause
Menstrual Cycle
Menstruation Disturbances
Meta-Analysis as Topic
Metabolic Clearance Rate
Methods
Methotrexate
Methylation
Methylenetetrahydrofolate Dehydrogenase (NADP)
Mice
Mice, Inbred BALB C
Mice, Nude
MicroRNAs
Microarray Analysis
Microfilament Proteins
Micromanipulation
Microsatellite Instability
Microsatellite Repeats
Microscopy, Atomic Force
Microscopy, Confocal
Microscopy, Electron
Microspheres
Middle Aged
Mitochondrial Proteins
Mitosis
Mitotic Index
Mixed Tumor, Mesodermal
Mixed Tumor, Mullerian
Models, Biological
Models, Economic
Models, Genetic
Models, Statistical
Molecular Conformation
Molecular Sequence Data
Molecular Targeted Therapy
Molecular Weight
Morbidity
Mucin-1
Mullerian Ducts
Multicenter Studies as Topic
Multivariate Analysis
Muscle, Skeletal
MutS Homolog 2 Protein
Mutagenesis, Insertional
Mutation
Mycobacterium bovis
Myelin Proteins
Myelin and Lymphocyte-Associated Proteolipid Proteins
Myometrium
Myosin Type II
N-Acetylgalactosaminyltransferases
NAD(P)H Dehydrogenase (Quinone)
NF-kappa B
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasm Proteins
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm Transplantation
Neoplasm, Residual
Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Multiple Primary
Neoplasms, Second Primary
Neoplastic Stem Cells
Neoplastic Syndromes, Hereditary
Neovascularization, Pathologic
Nerve Tissue Proteins
Neural Networks (Computer)
Neuropeptides
Neutropenia
Nicotinic Acids
North America
North Carolina
Nuclear Proteins
Nuclear Receptor Co-Repressor 1
Nuclear Receptor Co-Repressor 2
Nucleic Acid Heteroduplexes
Nucleic Acid Hybridization
Nutrition Disorders
Obesity
Observer Variation
Odds Ratio
Oligodeoxyribonucleotides
Oligonucleotide Array Sequence Analysis
Oligonucleotide Probes
Omentum
Oncogene Proteins, Viral
Oncogenes
Oncology Service, Hospital
Ornithine Decarboxylase
Ovarian Cysts
Ovarian Diseases
Ovarian Neoplasms
Ovariectomy
Ovary
Oviducts
Ovulation
Oxytocin
P-Glycoprotein
PTEN Phosphohydrolase
Paclitaxel
Pain, Postoperative
Palliative Care
Papillomaviridae
Paraffin Embedding
Parity
Patient Acceptance of Health Care
Patient Selection
Pedigree
Pelvic Exenteration
Pelvic Neoplasms
Pelvis
Peptide Elongation Factor Tu
Peptide Termination Factors
Peptides
Peripheral Nervous System Diseases
Peritoneal Cavity
Peritoneal Diseases
Peritoneal Lavage
Peritoneal Neoplasms
Peritoneum
Peritonitis, Tuberculous
Pharmacogenetics
Phenotype
Phosphates
Phosphatidate Phosphatase
Phosphatidylinositol 3-Kinases
Phosphoproteins
Phosphoric Monoester Hydrolases
Phosphorus Radioisotopes
Phosphorylation
Physical Examination
Pilot Projects
Piperidines
Placenta Accreta
Platelet Endothelial Cell Adhesion Molecule-1
Platelet-Derived Growth Factor
Platinum
Platinum Compounds
Ploidies
Pneumoperitoneum
Point Mutation
Poly(ADP-ribose) Polymerases
Polymerase Chain Reaction
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
Polymorphism, Single Nucleotide
Polymorphism, Single-Stranded Conformational
Population Dynamics
Population Surveillance
Postmenopause
Postoperative Complications
Postoperative Period
Powders
Practice Guidelines as Topic
Prealbumin
Precancerous Conditions
Precipitin Tests
Predictive Value of Tests
Pregnancy
Pregnancy Complications
Pregnancy Tests
Pregnancy Trimester, Second
Premenopause
Prenatal Diagnosis
Preoperative Care
Prevalence
Principal Component Analysis
Probability
Progesterone
Progestins
Prognosis
Proliferating Cell Nuclear Antigen
Promoter Regions, Genetic
Proportional Hazards Models
Prospective Studies
Prostaglandins
Prostaglandins E
Prostatic Neoplasms
Protamine Kinase
Protective Agents
Protein Array Analysis
Protein Isoforms
Protein Kinase C
Protein Kinase C-delta
Protein Kinase Inhibitors
Protein Precursors
Protein Processing, Post-Translational
Protein Structure, Tertiary
Protein Tyrosine Phosphatases
Protein-Serine-Threonine Kinases
Protein-Tyrosine Kinases
Proteins
Proteoglycans
Proteolipids
Proteomics
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myb
Proto-Oncogene Proteins pp60(c-src)
Proto-Oncogenes
Purines
Pyrimidines
Quality Control
Quality of Life
Quality-Adjusted Life Years
Quantitative Trait Loci
Questionnaires
Quinone Reductases
RNA
RNA Splicing
RNA, Antisense
RNA, Messenger
RNA, Neoplasm
RNA, Small Interfering
RNA, Untranslated
ROC Curve
Radiation Injuries
Radioimmunoassay
Radioimmunoprecipitation Assay
Radiopharmaceuticals
Radiotherapy
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Rats
Rats, Sprague-Dawley
Real-Time Polymerase Chain Reaction
Receptor Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Receptor, IGF Type 2
Receptor, erbB-2
Receptors, Androgen
Receptors, Calcitriol
Receptors, Cell Surface
Receptors, Estrogen
Receptors, Growth Factor
Receptors, Interleukin-1
Receptors, Interleukin-2
Receptors, Laminin
Receptors, Progesterone
Receptors, Transforming Growth Factor beta
Receptors, Tumor Necrosis Factor
Reconstructive Surgical Procedures
Rectus Abdominis
Recurrence
Reference Values
Registries
Regression Analysis
Remission Induction
Reoperation
Repetitive Sequences, Amino Acid
Repetitive Sequences, Nucleic Acid
Repressor Proteins
Reproducibility of Results
Reproductive History
Retinoblastoma Protein
Retirement
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Ricin
Risk
Risk Assessment
Risk Factors
Risk Reduction Behavior
Robotics
SEER Program
Sarcoma
Second-Look Surgery
Selective Estrogen Receptor Modulators
Sensitivity and Specificity
Sequence Analysis, DNA
Sequence Deletion
Serpins
Signal Transduction
Skin
Societies, Medical
Societies, Scientific
Socioeconomic Factors
Solubility
Specialization
Spheroids, Cellular
Staining and Labeling
Statistics, Nonparametric
Staurosporine
Sterilization, Tubal
Stimulation, Chemical
Stromal Cells
Sulfites
Surgical Flaps
Surgical Wound Dehiscence
Surgical Wound Infection
Surveys and Questionnaires
Survival
Survival Analysis
Survival Rate
Survivors
Sutures
T-Lymphocytes, Regulatory
TNF-Related Apoptosis-Inducing Ligand
Talc
Tamoxifen
Tandem Mass Spectrometry
Taxoids
Telomerase
Telomere
Terminal Care
Testis
Tetradecanoylphorbol Acetate
Tetrahydronaphthalenes
Therapies, Investigational
Thiazoles
Thigh
Thioguanine
Thiophenes
Thiotepa
Thrombocytosis
Thrombophlebitis
Thrombosis
Thrombospondin 1
Thymidine
Thymidylate Synthase
Time Factors
Tissue Array Analysis
Tissue Distribution
Tissue Embedding
Tissue Fixation
Tomography, Emission-Computed
Tomography, X-Ray Computed
Trans-Activators
Transcription Factors
Transcription, Genetic
Transcriptional Activation
Transfection
Transforming Growth Factor alpha
Transforming Growth Factor beta
Transforming Growth Factor beta1
Transforming Growth Factors
Transplantation, Autologous
Treatment Outcome
Tretinoin
Trinucleotide Repeats
Tritium
Trophoblastic Neoplasms
Tumor Cells, Cultured
Tumor Markers, Biological
Tumor Necrosis Factor-alpha
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
United Kingdom
United States
Up-Regulation
Urologic Diseases
Utah
Uterine Cervical Diseases
Uterine Cervical Incompetence
Uterine Cervical Neoplasms
Uterine Hemorrhage
Uterine Neoplasms
Uterine Rupture
Uterus
Vagina
Vaginal Fistula
Vaginal Neoplasms
Vaginal Smears
Vanadates
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1
Venous Thrombosis
Vincristine
Vulva
Vulvar Neoplasms
Wound Healing
X Chromosome
X-Linked Inhibitor of Apoptosis Protein
Xenobiotics
YY1 Transcription Factor
Young Adult
alpha-Fetoproteins
bcl-Associated Death Protein
ras Proteins
rho GTP-Binding Proteins
src-Family Kinases